Hendrik Peter Scholl, who serves as the Chief Medical Officer for BELITE BIO, INC (NASDAQ:BLTE), finalized a transaction to divest a portion of his equity holdings on June 16, 2026. The executive sold a total of 10,000 American depositary shares during this period. The financial value of this transaction was calculated at approximately $1,405,729. Each American depositary share issued by BELITE BIO represents one ordinary share of the company, ensuring a direct one-to-one correspondence between the traded instruments and the underlying equity.
The execution of these sales took place indirectly through Bioptima Ltd. The pricing for these transactions was not uniform; instead, the shares were sold at varying prices that ranged from $137.6053 to $145.0212 per share. The reported prices in the filing represent weighted averages for the shares sold within specified price ranges. The reporting individual has committed to providing complete and detailed information regarding the exact number of shares sold at each specific price point upon formal request.
This insider activity occurs against a backdrop of significant market movement for BELITE BIO. The stock has delivered a remarkable 136% return over the past year, indicating strong recent performance. However, shares have experienced a pullback of 14% year-to-date. According to analysis from InvestingPro, the stock remains undervalued at current levels relative to its fundamentals. For investors seeking deeper insights, InvestingPro offers 11 additional exclusive tips and comprehensive analysis through its Pro Research Report, available for BELITE BIO and over 1,400 US equities.
Following the completion of these transactions, Mr. Scholl, acting through Bioptima Ltd., maintains an indirect holding of 25,000 American depositary shares in BELITE BIO. This remaining stake reflects the net position after the divestment.
In other recent corporate developments, Belite Bio reported a significant earnings surprise for the first quarter of 2026. The company achieved an actual earnings per share (EPS) of -$0.34. This performance surpassed analysts’ expectations of -$0.64 by a margin of 46.88%. Despite this positive earnings performance relative to forecasts, Belite Bio reported a net loss of $26.9 million for the quarter. The company continues to make strategic investments in its lead program for Stargardt disease.
On the regulatory front, Belite Bio completed its rolling submission of a New Drug Application (NDA) to the FDA for tinlarebant, a treatment for Stargardt disease type 1. Following this progress, H.C. Wainwright maintained a Buy rating with a $200 price target. Mizuho, on the other hand, lowered its price target to $215 from $223 while maintaining an Outperform rating. Benchmark also reiterated a Buy rating, highlighting ongoing drug development efforts.
Market data for Belite Bio ADR shows a closing price of 138.19 USD on June 16, representing a decline of 6.05 or -4.19%. After hours trading on June 17 at 17:46:44 showed the price at 138.83 USD, an increase of 0.64 or +0.46%. Chart analysis tools are often utilized by traders to identify patterns and entry points, with some platforms claiming high accuracy rates for spotting trades before they play out.